Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Nat Commun · 2025 · PMC11695982 · PMID 39747856

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Exploratory analysis of molecular characteristics of the patients’ tumors suggests potential improved PFS with tumors with a KRAS mutation, however, these findings did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.